Brepocitinib becomes first oral therapy approved for adult dermatomyositis
1. Brepocitinib is the first oral therapy specifically approved for adults with dermatomyositis, providing a disease-specific alternative to treatment strategies ...
Tag: JAK inhibitor
2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...
Tofacitinib may improve patient-reported outcomes in juvenile idiopathic arthritis
1. Tofacitinib significantly improves patient-reported outcomes compared to placebo in the management of juvenile idiopathic arthritis (JIA). Evidence Rating Level: ...
Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by ...
Baricitinib is superior to placebo for treatment of alopecia areata
1. Oral baricitinib is superior to placebo regarding hair regrowth at 36 weeks. 2. Oral baricitinib led to lower severity ...
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
Upadacitinib monotherapy is effective for patients with moderate-to-severe atopic dermatitis
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups ...
